NEW YORK (GenomeWeb) – Myriad Genetics announced today that it has received positive coverage determinations for its EndoPredict breast cancer test from five Blue Cross Blue Shield affiliate plans.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.